58 results
Page 3 of 3
DEFA14A
joqup5kl3wkrej7k kwa
20 Apr 21
Additional proxy soliciting materials
7:07am
PRE 14A
pxbymugxx06h7lq35t
19 Apr 21
Preliminary proxy
5:28pm
8-K
EX-99.1
hk1c3bwc9tcup
25 Feb 21
Intra-cellular Therapies Reports Fourth Quarter and Full-year 2020 Financial Results and Provides Corporate Update
7:54am
8-K
EX-99.1
8ejg3oshh huj
22 Feb 21
Intra-Cellular Therapies Applies for FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression
8:09am
8-K
EX-99.1
wjvxf a03
9 Nov 20
Intra-cellular Therapies Reports Third Quarter 2020 Financial Results and Provides Corporate Update
7:40am
424B5
3wag2q462szg9 t2
11 Sep 20
Prospectus supplement for primary offering
4:44pm
424B5
uuwr7q5p
9 Sep 20
Prospectus supplement for primary offering
4:40pm
8-K
EX-99.1
vst2l7et4b2
9 Sep 20
Intra-Cellular Therapies Announces Positive Topline Results
7:13am
8-K
EX-99.1
138k6dq3
10 Aug 20
Intra-cellular Therapies Reports Second Quarter 2020 Financial Results and Provides Corporate Update
7:52am
8-K
EX-99.1
o1q lf751fb0ko
29 Jun 20
Intra-Cellular Therapies Announces PositiveTop-line Results fromITI-214 Phase I/II Study in Patients with Heart Failure
9:14am
DEFA14A
w1e m7u0wb4jh
13 May 20
Additional proxy soliciting materials
4:31pm
8-K
EX-99.1
93vav8a
7 May 20
Intra-cellular Therapies Reports First Quarter 2020 Financial Results and Provides Corporate Update
7:42am
8-K
qztl63xmg f1jhg
23 Mar 20
Intra-Cellular Therapies Announces Availability of CAPLYTA™ (lumateperone) for Adult Patients with Schizophrenia
7:52am
8-K
EX-99.1
nwznqm nlu8d
23 Mar 20
Intra-Cellular Therapies Announces Availability of CAPLYTA™ (lumateperone) for Adult Patients with Schizophrenia
7:52am